Searched for
LIALDA
Buy Cadila Healthcare, target price Rs 555: ICICI DirectCadila Healthcare Ltd., incorporated in the year 1995, is a Large Cap company (having a market cap of Rs 50828.82 Crore) operating in Pharm...- Cadila Healthcare surges 10% on 4-fold jump in Q2 profit"We remain positive on Cadila on account of robust launch momentum, build-up of a complex product pipeline including injectables and transd...
- Buy Cadila Healthcare, target price Rs 311: Nirmal Bang. The brokerage maintains its FY21 and FY22 estimates. It has rolled over to FY22 EPS and arrived at a target price of Rs 311 based on a ta...
- Add Cadila Healthcare, target Rs 292: ICICI SecuritiesCadila Healthcare is a largecap company, operating in pharmaceuticals and health care sector.
- Hold Cadila Healthcare, target Rs 380: Emkay Global Financial ServicesHold Cadila Healthcare Ltd. at a price target of Rs 380.0 .
- Buy Cadila Healthcare, target Rs 489: Anand RathiBuy Cadila Healthcare Ltd. at a price target of Rs 489.0 .
- Buy Cadila Healthcare, target Rs 460: Motilal OswalBuy Cadila Healthcare, at a price target of Rs 460.
- Stock pick of the week: What makes Cadila Healthcare analysts top betBetter than expected sales and net profit growth, limited impact of US FDA due to its limited exposure, and among other things, have made i...
- Buy Cadila Healthcare, target Rs 444: Equirus SecuritiesBuy Cadila Healthcare Ltd. at a price target of Rs 444.0 .
- Cadila Healthcare Q2 profit up 32% at Rs 503 crore
- Zydus Cadila launches anti-ulcer drug in USThe Gujarat-based group has more than 130 USFDA approvals and has filed over 300 abbreviated new drug applications (ANDAs) since it commenc...
- Buy Cadila Healthcare Ltd. target Rs 600 : Edelweiss Financial ServicesBuy Cadila Healthcare Ltd. at a price target of Rs 600. Edelweiss says Cadila's US business growth will be best-in-class at 48 per cent wit...
- Cadila Healthcare scales record high on USFDA approvalThe USFDA has given its final approval to market mesalamine delayed-release tablets USP 1.2 g in the US market.
- Will bring our latest drug Lialda by August: Nitin Kumar Parekh, Director - Finance, CadilaCadila will bring out its latest drug, Lialda, in July or August, revealed Nitin Kumar Parekh, Director - Finance, Cadila.
- Zydus Cadila gets USFDA nod for mesalamine tabletsZydus Cadila was the first to file an Abbreviated New Drug Application (ANDA) for the generic version of Lialda (mesalamine), the company s...
- need2know: Six things you must know to start day on Dalal StreetBank credit growth has slipped to 4.32% in the fortnight to April 28, against 63-year low of 5.08% in FY17
- US court rules in favour of Zydus Cadila in patent caseThe US Court of Appeals for the Federal Circuit has affirmed judgement in favour of Zydus Pharmaceuticals (USA) Inc.
- Margin improvement will happen once new approvals come in: Pankaj Patel of Cadila HealthcareWe should expect significant approval coming in, in FY18 we expect 40 plus approvals may be happening now.
- Stocks to watch: Reliance Industries, Hero Honda, HCL Tech, Reliance InfrastructureReliance Industries, freed from its non-compete agreement with the Anil Dhirubhai Ambani Group (ADAG) that barred it from investing in high...
- Zydus arm, Irish co in patent disputeThe Rs 3,700-crore Zydus Group’s US subsidiary Zydus Pharmaceuticals USA has challenged the Irish company Shire Pharmaceuticals over its pa...
Load More
